A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

Here are some data highlights and executive commentary from the larger companies I follow: AstraZeneca wins big (again) – The blockbuster drug Enhertu from AstraZeneca and Japanese drugmaker ...

On June 1, Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: TROPION-Lung02, TROPION-Lung04, and NeoCOAST-2. These studies ...

New study results from Turner and others show an experimental drug from AstraZeneca, camizestrant, can help sustain the benefit of first-line therapy. Unveiled Sunday, their research found that, once ...

Or will they learn their cancer is growing again? But a new study sponsored by the drug company AstraZeneca showed that there is an alternative: Instead of waiting for a scan to show that a cancer ...

Beta blockers have been shown to prolong survival in chronic heart failure. It is currently a matter of debate whether any β blocker is superior to the other in terms of improving symptoms ...

INTERRUPTION of beta-blocker treatment after an uncomplicated myocardial infarction (MI) leads to sustained increases in blood pressure and heart rate, with potentially harmful effects on clinical ...

What’s going on here? Sweden’s about to launch its largest AI supercomputer, led by AstraZeneca and Nvidia, aiming to transform drug discovery and more. Sweden's new AI supercomputer project, driven ...

In 2025, AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. So, revenue from Enhertu, which is a highly effective HER2 ...

Tariff-induced volatility may give lenders more leverage when it comes to incorporating so-called omni-blockers that aim to provide blanket, proactive protection against aggressive liability ...